Data as of Apr 17
| +0.01 / +0.49%|
The 1 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +145.10% increase from the last price of 2.04.
The current consensus among 1 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.